. "Nick Taylor"@en . "Charles Gersbach"@en . . . . "1118421353"^^ . . . . . "60171936"^^ . . . . . . "2021"^^ . . "crPhage"@en . . . . . . ""@en . . . . . . . . "Locus Biosciences"@en . . . . . "Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR\u2013Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections."@en . . . . . . . . "2015-05-22"^^ . . . . . . . . . "Privately held company"@en . . "Locus Biosciences"@en . . "Ahmed Gomaa"@en . "80"^^ . . . "2015"^^ . . . . "Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. Locus develops phage therapies based on CRISPR\u2013Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections."@en . . "80"^^ . . "United States"@en . . . . "Rodolphe Barrangou"@en . . . . "16998"^^ . . . . "Paul Garofolo"@en . . . . . "Dave Ousterout"@en . "2015-05-22"^^ . "Morrisville, North Carolina"@en . "Chase Beisel"@en . . . "Locus Biosciences logo.png"@en . . . . . "Locus Biosciences"@en .